Overview

Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

Status:
Completed

Trial end date:
2017-02-20

Target enrollment:

Participant gender:

Summary

What AE occur in routine clinical practice, what is the incidence of AE and Adverse Drug Reaction, how many patients present with AE symptoms related to a potential liver injury. What are the drug utilization patterns in patients, what are the predisposing factors for the occurrence of adverse events and adverse drug reactions.

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Acetaminophen
Butylscopolammonium Bromide
Scopolamine
Scopolamine Hydrobromide